Transfer of biopharmaceutical inventions between firms has bottlenecks in upstream development that suggest a role for repurposing mechanisms well before the clinical trials stage.

The biopharmaceutical sector has become a significant segment of pharmaceutical industry. More than 200 biopharmaceutical products have reached market approval and more than 350 additional products are currently in clinical trials [1]. Chinese hamster ovary (CHO) cells are the main host for production of recombinant therapeutic proteins. The 2011 CHO-produced biopharmaceutical sales were nearly...

BACKGROUND Patient engagement is an essential aspect in the research/development of biopharmaceutical products and disease management. Improving the lives of patients requires a deep understanding of their medical conditions, experiences, needs and priorities. However, a consistent definition of patient centricity is lacking. A series of initiatives was conducted to define patient centricity an...

The introduction of targeted biological therapies has revolutionised the treatment of patients with inflammatory joint diseases. These medications are highly effective in reducing disease activity, improving physical function, and retarding or arresting the progression of structural damage. Their relative benefits and risks have been ascertained and contraindications to their use are well known...

BACKGROUND Rare diseases are a global public health concern, affecting an estimated 350 million individuals. Only 5% of approximately 7000 known rare diseases have a treatment, and only about half have a patient advocacy organization. Biopharmaceutical companies face complex challenges in developing treatments for rare diseases. Patient advocacy organizations may play a major role by positively...

There is a need to use more descriptive and precise terms describe some of the properties products used for biopharmaceutical analysis. It probably correct say “low adsorption” “corrosion-resistant” systems.